NUVB
Nuvation Bio Inc.Healthcare · $1.9B market cap
Verdict
We can't put a fair value on NUVB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow NUVB
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold NUVB. In Q1 2026, 1 trimmed. Who we track
David Abrams
Abrams Capital Management · as of Q2 2026
$7.2M
1,270,504 shares
David Einhorn
Greenlight Capital · as of Q4 2023
$53K
34,995 shares
Moves in Q1 2026
Trimmed: David Abrams
About Nuvation Bio Inc.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works